Equity Research Analysis: BioSig Technologies, Inc. (STEX)
|Blank Capital Research Unit|Spot: $2.23
Price$2.23
Composite Score38.6/100
RatingAVOID (1★)
Rank#3718 OF 7,333
Market Cap$192M
ROE
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3718
Positioning
Market Dominance
Manufacturing
Medical Equipment
$192M
Kenneth L. Londoner
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system. PURE EP is a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$STEX BioSig Technologies, Inc. | 39 | 30 | 45 | 49 | - | - | 1121.9% | -31.2% | - | - | - | -100.0% | 0.0% | - | $192M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
BioSig Technologies, Inc. (STEX) receives a "Avoid" rating with a composite score of 38.6/100. It ranks #3718 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Equity capital efficiency
Asset base utilization
Direct cash return
Kenneth L. Londoner
Chief Executive Officer
Labor Force
50
30
25
15
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for STEX
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
No analyst ratings for STEX.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy 1121.9% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth -100%, 10yr history
Interest coverage -611.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags BioSig Technologies, Inc. with an Avoid rating, assigning a composite score of 38.6/100 and 1 out of 5 stars. Ranked #3718 of 7,333 stocks, STEX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
STEX's quality score of 30/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 1121.9% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 45/100, STEX appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
BioSig Technologies, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 5.9% and a return on assets of -31.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
STEX is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -100.0% year-over-year, while a beta of 2.47 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
BioSig Technologies, Inc. registers a low stability score of 15/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.47. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 53/100 for STEX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 2.47), micro-cap liquidity risk. With a $192M market cap (micro-cap), BioSig Technologies, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
BioSig Technologies, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3718 of 7,333 overall (49th percentile). Key comparisons include ROE of 1121.9% exceeding the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While STEX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (15) would have the largest impact on the composite score.
ROE 45339% BELOW SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate BioSig Technologies, Inc. (STEX) as Avoid with a composite score of 38.6/100 at a current price of $2.23. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (49th percentile) and value (45th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (15th percentile) and investment (25th percentile) tempers our overall conviction. We assign a No Moat rating (30/100), High uncertainty, and Poor capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
BioSig Technologies, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 38.6/100 places it at rank #3718 in our full 7,333-stock universe. At $192M in market capitalization, BioSig Technologies, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -100% combined with momentum at the 49th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
Margin data is not available for BioSig Technologies, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $2.23, BioSig Technologies, Inc. is trading near fair value based on current fundamentals. Our value factor score of 45/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
Valuation multiples are not available for this company, which limits our ability to assess relative pricing. We rely more heavily on factor-based valuation signals in such cases.
Returns on equity of 1121.9% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
The Avoid rating (composite 38.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -100% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Below-average quality (30th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 2.47 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to BioSig Technologies, Inc.. Key risk factors include elevated market sensitivity (beta of 2.47), below-average price stability (15th percentile), weak quality scores (30th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 2.47); below-average price stability (15th percentile); weak quality scores (30th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 15th percentile and quality factor at the 30th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate BioSig Technologies, Inc.'s capital allocation as Poor. Key concerns include weak asset returns (ROA -31.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — BioSig Technologies, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, BioSig Technologies, Inc. receives a Avoid rating with a composite score of 38.6/100 (rank #3718 of 7,333). Our quantitative framework assigns a No Moat (30/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on BioSig Technologies, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign BioSig Technologies, Inc. a meaningful economic moat, scoring 30/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, economic value creation, reached only 17.5/20.
The strongest moat sources are economic value creation (17.5/20) and margin superiority (11.5/20). ROE proxy 1121.9% (sector -2.5%). GM N/A vs sector 43%, OM N/A vs sector 1%. These pillars form the core of BioSig Technologies, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect BioSig Technologies, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-100%) that pressure the earnings outlook, returns on equity of 1121.9% driving shareholder value creation. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 30th percentile.
Return metrics include ROE of 1121.9% and ROA of -31.2%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of 1121.9% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of -100%. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Bitcoin is evolving into something very different from its original speculative form, and a tokenized yield-bearing gold stablecoin, Streamex GLDY, launching on 25 February, shines a light on what that future holds. Market watchers will have noticed that gold has been trading like Bitcoin these past few weeks, displaying the ...
Streamex (STEX) is back on investors’ radar after a pair of leadership changes, with co founder Morgan Lekstrom becoming Executive Chairman and NYU finance professor Anthony Marciano joining the board and Audit Committee. See our latest analysis for Streamex. Those boardroom changes arrive after a sharp run, with a very large 1 year total shareholder return contrasting with a 3 year total shareholder return that is still down 78%, and recent share price weakness, including a 90 day share...
Why Streamex Is Back on Investors’ Radar Streamex (STEX) is drawing fresh attention after adding finance academic Anthony Marciano to its board, completing a public equity raise of about US$35 million, and outlining plans to prepay US$50 million in convertible debt. See our latest analysis for Streamex. Despite the recent corporate moves, Streamex’s short term share price performance has been weak, with a 17.1% 7 day and 33.6% 90 day share price decline. Its 1 year total shareholder return...
In January 2026, Streamex Corp. completed a US$35.00 million follow-on offering of 11,666,667 common shares at US$3.00 each, shortly after announcing a collaboration with tZERO Group to enable secondary trading of its GLDY gold-linked tokenized security on a regulated alternative trading system. This combination of fresh equity capital and access to institutional-grade, regulated trading infrastructure for GLDY marks an important step in Streamex’s effort to build a compliant market for...